Country-level evidence adaptation for 8 CEE pharma affiliates — one core clinical brief, 8 locally adapted versions
One global brief, eight different reimbursement realities
A global pharma brand had prepared a comprehensive clinical evidence brief for an oncology product. The document was scientifically rigorous and globally aligned — but it was built around the US and Western European market assumptions. Comparators, trial endpoints highlighted, and the economic framing were all calibrated for the global audience.
Eight CEE affiliates — Poland, Czech Republic, Hungary, Romania, Bulgaria, Slovakia, Croatia, and Slovenia — each had distinct payer bodies, different standard-of-care comparators, different reimbursement criteria, and in some cases, different language requirements for internal materials.
Global documents don't fail because the science is wrong — they fail because the local context is missing. Eight markets needed eight versions, without eight separate workstreams.
What we did
Measurable impact
All 8 country-adapted versions were delivered within the project timeline. The modular approach reduced total production time compared to sequential adaptation by an estimated 60%. Every affiliate launched with localised materials during the same quarter, meeting the regional Medical Director's primary objective. The framework was subsequently used for two additional launches in the same region.
Tell us what you’re working on — we’ll show you relevant cases and suggest the fastest path forward.
From the field:
evidence & practice
AI-powered.
Expert-validated.
We built AI workflows into our daily practice — not as a marketing claim, but as the infrastructure that lets our medical experts deliver faster without cutting corners.